Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 1:13:970906.
doi: 10.3389/fimmu.2022.970906. eCollection 2022.

IL-10 revisited in systemic lupus erythematosus

Affiliations
Review

IL-10 revisited in systemic lupus erythematosus

Swayanka Biswas et al. Front Immunol. .

Abstract

IL-10 is a cytokine with pleiotropic functions, particularly known for its suppressive effects on various immune cells. Consequently, it can limit the pathogenesis of inflammatory diseases, such as multiple sclerosis (MS), inflammatory bowel disease, Crohn's disease, and Epidermolysis bullosa acquisita, among others. Recent evidence however indicates that it plays dual roles in Systemic lupus Erythematosus (SLE) where it may inhibit pro-inflammatory effector functions but seems to be also a main driver of the extrafollicular antibody response, outside of germinal centers (GC). In line, IL-10 promotes direct differentiation of activated B cells into plasma cells rather than stimulating a GC response. IL-10 is produced by B cells, myeloid cells, and certain T cell subsets, including extrafollicular T helper cells, which are phenotypically distinct from follicular helper T cells that are relevant for GC formation. In SLE patients and murine lupus models extrafollicular T helper cells have been reported to support ongoing extrafollicular formation of autoreactive plasma cells, despite the presence of GCs. Here, we discuss the role of IL-10 as driver of B cell responses, its impact on B cell proliferation, class switch, and plasma cells.

Keywords: B cells; IL-10; autoimmunity; extrafollicular T cells; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The opposing role of IL-10 in SLE. The cytokine drives the continuous formation of pro-inflammatory autoantibodies, particularly outside GCs, but can also limit inflammatory effector functions. Figure created with BioRender.com.

References

    1. Adler AS, Mizrahi RA, Spindler MJ, Adams MS, Asensio MA, Edgar RC, et al. Rare, high-affinity anti-pathogen antibodies from human repertoires, discovered using microfluidics and molecular genomics. mAbs (2017) 9:1282–96. doi: 10.1080/19420862.2017.1371383 - DOI - PMC - PubMed
    1. Ueki Y, Goldfarb IS, Harindranath N, Gore M, Koprowski H, Notkins AL, et al. Clonal analysis of a human antibody response. quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. J Exp Med (1990) 171:19–34. doi: 10.1084/jem.171.1.19 - DOI - PMC - PubMed
    1. Wang P, Nakamura K, Mimura Y, Takeo K, Tanaka T, Fujimoto M. Immune response to different doses of a hapten of fluorescein isothiocyanate analyzed by two-dimensional affinity electrophoresis. Electrophoresis (1996) 17:1273–9. doi: 10.1002/elps.1150170717 - DOI - PubMed
    1. Quilez R, de Lauzon S, Desfosses B, Mansey D, Mahy J-P.Artificial peroxidase-like hemoproteins based on antibodies constructed from a specifically designed ortho-carboxy substituted tetraarylporphyrin hapten and exhibiting a high affinity for iron-porphyrins. FEBS Letters (1996) 395(1):73–6. - PubMed
    1. Casali P, Nakamura M, Ginsberg-Fellner F, Notkins AL. Frequency of b cells committed to the production of antibodies to insulin in newly diagnosed patients with insulin-dependent diabetes mellitus and generation of high affinity human monoclonal IgG to insulin. J Immunol (1990) 144:3741–7. - PubMed

Publication types